Profile Image

Staff Profile

Edit

Career Summary

Biography

Prof. Stephen Ackland is Staff Specialist, Department of Medical Oncology, Calvary Mater Newcastle Hospital and Conjoint Professor, Faculty of Health, University of Newcastle. He is the Director, Hunter Translational Cancer Research Unit; Director, University of Newcastle Priority Research Centre for Cancer; Director of Clinical Cancer Research Network HNE Health; Co-director of Hunter Medical Research Institute Cancer Research Program. He has played a key role in organisation, harmonisation and enhancements of translational and clinical research locally, on a state basis and nationally. He is Editor-in-Chief, Asia-Pacific Journal of Clinical Oncology. He is an inaugural member of the PRIMe consortium (Pharmacogenomics Research towards Individualised Medicine), a NSW Cancer Council-funded collaboration of 8 NSW hospitals and research institutes with the aim of facilitating cancer pharmacogenomics research in NSW.

He has had a number of committee appointments including: Honorary Secretary, Medical Oncology Group of Australia, 1997-2000; Chairman, Medical Oncology Group of Australia, 1999-2000. Chair, Specialist Advisory Committee in Medical Oncology, RACP, 1999-2000; AMWAC Committee on Medical Oncology 1999-2001; President, Clinical Oncological Society of Australia 2004-2005; Director, Australian & New Zealand Breast Cancer Trials Group, 2007-2013; Director, NSW Cancer Council, 2006-2013.

He is the author of over 90 original publications in peer-reviewed journals and first author on 18 of these. He was co-owner of 2 patents. He has been investigator on 25 grants totalling $10.9m, including lead investigator on 8 grants valued at approx $4m. He has had extensive involvement in cancer clinical trials, clinical pharmacokinetics and pre-clinical pharmacology of anticancer drugs and combinations. He has been the principal investigator on two Australian multi-institutional randomised controlled trials run through cancer cooperative trials groups, and principal investigator on a number of phase I & II trials. He is/has been a member of the trial management committee of a number of cancer cooperative trials groups, undertaking multi-institutional trials in breast and GI cancer.

Qualifications

  • Bachelor of Medicine & Surgery, University of Melbourne

Research

Research keywords

  • Clinical Trials
  • Pharmacogenomics
  • Pharmacokinetics
  • Pharmacology

Research expertise

  • Basic and clinical pharmacology of anticancer drugs, including drug measurement, pharmacokinetics pharmacodynamics, and relevant genetics/genomics.
  • Clinical trials in cancer mainly medical oncology.

Languages

  • English

Fields of Research

CodeDescriptionPercentage
110399Clinical Sciences Not Elsewhere Classified35
111599Pharmacology And Pharmaceutical Sciences Not Elsewhere Classified35
111200Oncology And Carcinogenesis30

Memberships

Committee/Associations (relevant to research).

  • Am Assoc Cancer Research

Editorial Board.

  • Editor - Asia Pacific Journal of Clinical Oncology
  • Board member - Drug Resistance Updates

Learned Academy.

  • Member - Clinical Oncological Society of Australia (Clinical Oncological Society of Australia)
  • Member, ASCO International Affairs Committee 1997-99 and 2006-08

Appointments

Director
ANZ Breast Cancer Trials Group (Australia)
01/07/2007
Member, scientific Advisory Committee
Australasian GI Trials Group (Australia)
01/01/1994
Chairman
Medical Oncology Group of Australia (Australia)
01/01/1999 - 01/01/2001
President
Clinical Oncological Soc of Australia (Australia)
01/01/2004 - 01/01/2006
Editor
Asia Pacific Journal of Clinical Oncology (Australia)
01/09/2004
Director
Cancer Council NSW (Australia)
01/09/2006
Member
International Affairs Committee, Am Soc Clin Oncology (United States)
01/09/2006 - 01/09/2009

Administrative

Administrative expertise

Director of Medical Oncology 2001-2005. Manages the Medical Oncology research program (9 staff, clinical and lab).Chair of HMRI Cancer Research Program 2003 -present. President of Clinical Oncological Soc of Australia 2004 and 2005. Chairman, Medical Oncology Group of Australia 1999 and 2000. Board member, TheraPPy Pty Ltd 2004-2006. Board member Cancer Council NSW 2006-2009. Member, International Affairs Committee, Am Soc of Clin Oncol, 1998-2000 and 2006-2009

Teaching

Teaching keywords

  • Medical Oncology
  • Medicine

Teaching expertise

Teaches medical nursing and allied health students and postgraduates in basic and clinical oncology. Also science students in pharmacology

Edit

Highlighted Publications

For publications that are currently unpublished or in-press, details are shown in italics.

YearCitationAltmetricsLink
2006Wong M, Balleine RL, Blair EYL, McLachlan AJ, Ackland S, Garg M, et al., 'Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer', Journal of Clinical Oncology, 24 2448-2455 (2006) [C1]

Publications

For publications that are currently unpublished or in-press, details are shown in italics.

Click on a category title below to expand the list of citations for that specific category.

Chapter (1 outputs)

YearCitationAltmetricsLink
2003Ackland S, Beale P, Godefridus J, 'Thymidylate synhase inhibitors', Cancer chemotherapy and Biological response modifiers, Elsevier BV, netherlands 1-28 (2003) [B2]

Journal article (95 outputs)

YearCitationAltmetricsLink
2014Yip D, Zalcberg J, Fox S, Mcarthur G, Desai J, Ackland S, et al., 'Controversies in the management of gastrointestinal stromal tumors', Asia-Pacific Journal of Clinical Oncology, (2014)
2013Price TJ, Segelov E, Burge M, Haller DG, Ackland SP, Tebbutt NC, et al., 'Current opinion on optimal treatment for colorectal cancer', EXPERT REVIEW OF ANTICANCER THERAPY, 13 597-611 (2013) [C1]
2013Ackland S, Goldstein D, McJannett M, 'Forty years of COSA - Contributions to oncology teaching and research', Cancer Forum, 37 238-242 (2013) [C2]
2013Ackland S, Fukuda Y, ' 2012: Year in Review - from dragons to snakes', Asia-Pacific Journal of Clinical Oncology, 9 1-1 (2013) [C3]
2012Price TJ, Zannino D, Wilson K, Simes RJ, Cassidy J, Van Hazel GA, et al., 'Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C', ANNALS OF ONCOLOGY, 23 1531-1536 (2012) [C1]
2012Zdenkowski N, Chen S, Van Der Westhuizen A, Ackland S, 'Curative strategies for liver metastases from colorectal cancer: A review', Oncologist, 17 201-211 (2012) [C1]
2012Goldstein D, Spry N, Cummins MM, Brown C, Van Hazel GA, Carroll S, et al., 'The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer', British Journal of Cancer, 106 61-69 (2012) [C1]
2012Garg MB, Lincz L, Adler K, Scorgie FE, Ackland S, Sakoff JA, 'Predicting 5-Fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length - A multivariate analysis', British Journal of Cancer, 107 1525-1533 (2012) [C1]
2012Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et al., 'Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group Trial 01.04', Journal of Clinical Oncology, 30 3827-3833 (2012) [C1]
2012Ackland S, Fukuda Y, '2011: Year in review - From rabbits to dragons', Asia-Pacific Journal of Clinical Oncology, 8 1-2 (2012) [C3]
2011Garg MB, Ackland S, 'Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect', Cancer Chemotherapy and Pharmacology, 67 963-966 (2011) [C1]
2011Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland S, Fitzharris B, et al., 'Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer', Journal of Clinical Oncology, 29 4498-4504 (2011) [C1]

Co-authors: John Forbes

2011Agrez M, Garg M, Dorahy D, Ackland S, 'Synergistic anti-tumor effect of cisplatin when combined with an anti-src kinase integrin-based peptide', Journal of Cancer Therapy, 2 295-301 (2011) [C1]
2011Goldstein D, Gainford MC, Brown C, Tebbutt N, Ackland S, Van Hazel G, et al., 'Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas', Cancer Chemotherapy and Pharmacology, 67 519-525 (2011) [C1]
2011Lee CK, Hudson M, Stockler M, Coates AS, Ackland S, Gebski V, et al., 'A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer', Breast Cancer Research and Treatment, 129 467-476 (2011) [C1]
2011Garg MB, Sakoff JA, Ackland S, 'A simple HPLC method for plasma level monitoring of mitotane and its two main metabolites in adrenocortical cancer patients', Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 879 2201-2205 (2011) [C1]

Co-authors: Jennette Sakoff

2011Vilain RE, Dudding TE, Braye SG, Groombridge C, Meldrum C, Spigelman AD, et al., 'Can a familial gastrointestinal tumour syndrome be allelic with Waardenburg syndrome?', Clinical Genetics, 79 554-560 (2011) [C3]
2011Ackland S, 'Cancer in Australia: A model for other Asia-Pacific countries', Asia-Pacific Journal of Clinical Oncology, 7 323-324 (2011) [C3]
2011Price TJ, Zannino D, Wilson K, Simes J, Van Hazel GA, Robinson BA, et al., 'Geriatric subgroup of AGITG MAX trial: International randomized phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in first-line metastatic colorectal cancer (CRC)', JOURNAL OF CLINICAL ONCOLOGY, 29 (2011) [E3]
2011Price TJ, Zannino D, Wilson K, Simes J, Van Hazel GA, Robinson BA, et al., 'Outcome and dose intensity (DI) in the elderly subgroup of the AGITG MAX phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in first-line metastatic colorectal cancer (CRC)', JOURNAL OF CLINICAL ONCOLOGY, 29 (2011)
2011Ackland S, Fukuda Y, '2011: Year in Review - from rabbits to dragons', Asia-Pacific Journal of Clinical Oncology, 8 1-2 (2011)
2010Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, Van Hazel GA, et al., 'Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study', Journal of Clinical Oncology, 28 3191-3198 (2010) [C1]
2010De Bock CE, Garg ML, Scott NM, Sakoff JA, Scorgie FE, Ackland S, Lincz L, 'Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo', Pharmacogenomics Journal, 1-8 (2010) [C1]
2010Ngan S, Fisher R, Goldstein D, Solomon M, Burmeister B, Ackland SP, et al., 'A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: An intergroup trial (TROG, AGITG, CSSANZ, RACS)', JOURNAL OF CLINICAL ONCOLOGY, 28 (2010)
2009Ackland S, Bull JM, Boyle FM, 'Nab-Paclitaxel: A bright new sparc in taxane therapy of cancer', Asia-Pacific Journal of Clinical Oncology, 5 147-150 (2009) [C1]
2009Sobrero A, Ackland S, Clarke S, Perez-Carrion R, Chiara S, Gapski J, et al., 'Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer', ONCOLOGY, 77 113-119 (2009) [C1]
2009Ackland S, 'Molecular biomarkers in non-small cell lung cancer: Pointing the way to better outcomes from treatment', Asia-Pacific Journal of Clinical Oncology, 5 213-214 (2009) [C3]
2008Hill TA, Stewart SG, Gordon CP, Ackland SR, Gilbert J, Sauer B, et al., 'Norcantharidin analogues: Synthesis, anticancer activity and protein phosphatase 1 and 2A inhibition', ChemMedChem, 3 1878-1892 (2008) [C1]
2008Vilain RE, Ackland S, 'Gastrointestinal stromal tumors - A model for understanding solid tumor biology and development of targeted therapies, or just another low-hanging fruit?', Asia-Pacific Journal of Clinical Oncology, 4 185-187 (2008) [C3]
2008Ackland S, Tracey E, 'Cancer registries: Their role in health care delivery in the Asia-Pacific region', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 4 71-74 (2008) [C3]
2007Young JM, Leong DC, Armstrong K, O'Connell D, Armstrong BK, Spigelman AD, et al., 'Concordance with national guidelines for colorectal cancer care in New South Wales: a population-based patterns of care study', Medical Journal of Australia, 186 292-295 (2007) [C1]
2007Temmink OH, Hoebe EK, Van Der Born K, Ackland S, Fukushima M, Peters GJ, 'Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells', British Journal of Cancer, 96 231-240 (2007) [C1]
2007Hill TA, Stewart SG, Ackland S, Gilbert J, Sauer B, Sakoff JA, McCluskey A, 'Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation', Bioorganic and Medicinal Chemistry, 15 6126-6134 (2007) [C1]
2007Hill TA, Stewart SG, Sauer B, Gilbert J, Ackland S, Sakoff JA, McCluskey A, 'Heterocyclic substituted cantharidin and norcantharidin analogues-synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity', Bioorganic and Medicinal Chemistry Letters, 17 3392-3397 (2007) [C1]
2007Stewart SG, Hill TA, Gilbert J, Ackland S, Sakoff JA, McCluskey A, 'Synthesis and biological evaluation of norcantharidin analogues: Towards PP1 selectivity', Bioorganic and Medicinal Chemistry, 15 7301-7310 (2007) [C1]
2007Davis AJ, Brew S, Gebski VJ, Lewis CR, Moylan E, Parnis FX, Ackland S, 'Multicenter phase II study of combination chemotherapy with capecitabine and intravenous vinorelbine in patients with pretreated metastatic breast cancer', Asia-Pacific Journal of Clinical Oncology, 3 37-43 (2007) [C1]
2007Findlay M, Sharples K, Riley GA, Simpson A, Ackland S, Hall K, et al., 'Capecitabine and oral cyclophosphamide: A novel oral treatment combination for advanced cancer', Asia-Pacific Journal of Clinical Oncology, 3 99-105 (2007) [C1]
2007Lincz L, Scorgie FE, Garg MB, Ackland S, 'Identification of a novel single nucleotide polymorphism in the second tandem repeat sequence of the thymidylate synthase 2R allele', International Journal of Cancer, 120 1930-1934 (2007) [C1]
2007Lincz L, Scorgie FE, Garg ML, Ackland S, 'Reply to the letter to the editor 'Classification of thymidylate synthase gene enhancer region polymorphisms'', International Journal of Cancer, 121 2581-2582 (2007) [C3]
2007Carrington C, Carlton J, Ackland S, 'Preventing chemotherapy errors: Implementing system changes', Asia-Pacific Journal of Clinical Oncology, 3 57-58 (2007) [C3]
2006Wong M, Balleine RL, Blair EYL, McLachlan AJ, Ackland S, Garg M, et al., 'Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer', Journal of Clinical Oncology, 24 2448-2455 (2006) [C1]
2006Goldstein D, Ackland S, Bell DR, Olver IN, Davis ID, Rosenthal MA, et al., 'Phase II study of vinflunine in patients with metastatic renal cell carcinoma', Investigational New Drugs, 24 429-434 (2006) [C1]
2006Ackland S, Clarke SJ, Beale P, Peters GJ, 'Thymidylate synthase inhibitors', Update on Cancer Therapeutics, 1 403-427 (2006) [C1]
2006Ackland S, 'Cervical carcinoma: A common and preventable problem in developing countries (Editorial)', Asia-Pacific Journal of Clinical Oncology, 2 69-70 (2006) [C3]
2005Ackland SP, Jones M, Tu D, Simes J, Yuen J, Sargeant A-M, et al., 'A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer', British Journal of Cancer, 93 1236-1243 (2005) [C1]
2005Odelli C, Burgess D, Bateman L, Hughes A, Ackland S, Gillies J, Collins CE, 'Nutrition Support Improves Patient Outcomes, Treatment Tolerance and Admission Characteristics in Oesophageal Cancer', Clinical Oncology, 17 639-645 (2005) [C1]
2005Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, et al., 'Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial', Lancet Oncology, 6 659-668 (2005) [C1]
2004Liu JJ, Kestell P, Findlay M, Riley G, Ackland S, Simpson A, et al., 'Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients', Clinical and Experimental Pharmacology and Physiology, 31 677-682 (2004) [C1]
2004O'Brien M, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al., 'Reduced cardiotoxicity and comparable efficacy in a phase 3 trial of pegylated liposomal doxorubicine HCI (CAELYX / Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer', Annals of Oncology, 15 440-449 (2004) [C1]
2004Sakoff JA, Howitt IJ, Ackland S, McCluskey A, 'Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition', Cancer Chemotherapy and Pharmacology, 53 225-232 (2004) [C1]
2004Lincz L, Scorgie F, Sakoff J, Fagan K, Ackland S, Enno A, 'Telomere length predicts neutrophil recovery in absence of G-CSF after autologous peripheral blood stem cell transplantation', Bone Marrow Transplant, 34 439-445 (2004) [C1]
2003Ackland S, Bowyer MC, Baldwin ML, Garner JA, Walkom CC, Sakoff JA, McCluskey A, 'Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines', Bioorganic Chemistry, 31 68-79 (2003) [C1]
2003Denham J, Steigler A, Kilmurray J, Wratten C, Burmeister B, Lam D, et al., 'Relapse patterns after chemo-radiation for carcinoma of the oesophagus', Clinical Oncology, 15 98-108 (2003) [C1]
2002Garg MB, Sevester JC, Sakoff JA, Ackland S, 'Rapid and simple chromatographic method for the determination of uracil and dihydrouracil plasma levels: A potential pretreatment predictor of 5FU toxicity', Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Science, 774 223-230 (2002) [C1]
2002Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Milward MJ, Ackland S, 'Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-na¿ve patients with advanced non-small-cell lung cancer', Annals of Oncology, 13 737-741 (2002) [C1]
2002Marx G, Lewis C, Hall K, Levi J, Ackland S, 'Phase I study of docetaxel plus ifosfamide in patients with advanced cancer', British Journal of Cancer, 87 846-849 (2002) [C1]
2002Rischin D, Ackland S, Smith J, Garg MB, Clarke SJ, Millward MJ, et al., 'Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with G-CSF but not with prophylactic antibiotics', Annals of Oncology, 13 1810-1818 (2002) [C1]
2002McCluskey A, Ackland S, Gardiner E, Walkom CC, Sakoff J, 'The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?', Anti-Cancer Drug Design, 16 291-303 (2002) [C1]
2002Sakoff J, Ackland S, Baldwin ML, Atherton MA, McCluskey A, 'Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues', Investigational New Drugs, 20 1-11 (2002) [C1]
2002Sakoff J, De Waal E, Garg M, Denham J, Scorgie F, Enno A, et al., 'Telomere Length in Haemopoietic Stem Cells can be Determined from that of Mononuclear Blood Cells or Whole Blood', Leukemia and Lymphoma, 43(10) 2017-2020 (2002) [C1]
2002Talbot DC, Moiseyenko V, Van Belle S, O'Reilly SM, Alba Conejo E, Ackland S, et al., 'Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines', British Journal of Cancer, 86 1367-1372 (2002) [C1]
2002Garg MB, Sevester JC, Sakoff JA, Ackland SP, 'Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity', JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 774 223-230 (2002)
2002Ackland SP, Clarke SJ, Beale P, Peters GJ, 'Thymidylate synthase inhibitors.', Cancer chemotherapy and biological response modifiers, 20 1-36 (2002)
2001McCluskey A, Walkom CC, Bowyer MC, Ackland SP, Gardiner E, Sakoff JA, 'Cantharimides: A new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A', Bioorganic & Medicinal Chemistry Letters, 11 2941-2946 (2001) [C1]
2001Ackland S, Anton A, Breitbach G, Colajori E, Tursi J, Delfino C, et al., 'Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophoshamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: A randomized multinational study', Journal of Clinical Oncology, 19 943-953 (2001) [C1]
2000Garg M, Ackland S, 'Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine', Journal of Chromatography B, 748 383-388 (2000) [C1]
2000Sakoff J, Ackland S, 'Thymidylate synthase inhibition induces S-phase arrest, biphasic mitochondrial alterations and caspase-dependent apoptosis in leukaemia cells', Cancer Chemotherapy and Pharmacology, 46 477-487 (2000) [C1]

Co-authors: Jennette Sakoff

2000Peters G, De Bruin M, Fukushima M, Van Triest B, Hoekman K, Pinedo H, Ackland S, 'Thymidine phosphorylase in angiogenesis and drug resistance', Advances in Experimental Medicine and Biology, 486 291-294 (2000) [C2]
2000Peters GJ, van der Wilt CL, van Moorsel CJA, Kroep JR, Bergman AM, Ackland SP, 'Basis for effective combination cancer chemotherapy with antimetabolites', PHARMACOLOGY & THERAPEUTICS, 87 227-253 (2000)
2000Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al., 'Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.', NEW ENGLAND JOURNAL OF MEDICINE, 343 905-914 (2000)
2000Sakoff JA, McCluskey A, Sims ATR, Stewart JF, Ackland SP, 'A counter intuitive therapy for the treatment of cancer: Inhibition of protein phosphatases 1 and 2A by cantharidin (Spanish Fly) analogues.', CLINICAL CANCER RESEARCH, 6 4495S-4495S (2000)
1999Newell SA, Sanson-Fisher RW, Girgis A, Ackland S, 'The physical and psycho-social experiences of patients attending an outpatient medical oncology department: a cross-sectional study', European Journal of Cancer Care, 8 73-82 (1999) [C1]

Co-authors: Rob Sanson-Fisher

1999Denham JW, Ackland SP, Burmeister B, Walpole E, Lamb DS, Dady P, Spry NA, 'Causes for increased myelosuppression with increasing age in patients with oesophageal cancer treated by chemoradiotherapy', EUROPEAN JOURNAL OF CANCER, 35 921-927 (1999)
1999Ackland SP, Peters GJ, 'Thymidine phosphorylase: its role in sensitivity and resistance to anticancer drugs', DRUG RESISTANCE UPDATES, 2 205-214 (1999)
1999Lamb D, Atkinson C, Joseph D, O'Brien P, Ackland S, Bonaventura A, et al., 'Simultaneous adjuvant radiotherapy and chemotherapy for stage I and II breast cancer', Australasian Radiology, 43 220-226 (1999)
1999Ackland S, Rischin D, Beith J, Gupta S, Wyatt S, Davison J, et al., 'Phase I study of docetaxel epirubicin and cyclophosphamide (TEC) in patients with advanced cancer (AC)', EUROPEAN JOURNAL OF CANCER, 35 S292-S292 (1999)
1998Garg M, Ackland S, 'A sensitive method for the determination of docetaxel (Taxotere (R)) in human plasma by high performance liquid chromatography', ANNALS OF ONCOLOGY, 9 94-94 (1998)
1998Ackland S, Garg M, van Moorsel CJA, Kuiper CM, Smid K, Peters GJ, 'Tomudex and cisplatin have additive cytotoxicity and no biochemical interaction in ovarian cancer cell lines', ANNALS OF ONCOLOGY, 9 155-155 (1998)
1998van der Heijden M, Ackland SP, Deveridge S, 'Haemolytic uraemic syndrome associated with bleomycin, epirubicin and cisplatin chemotherapy - A case report and review of the literature', ACTA ONCOLOGICA, 37 107-109 (1998)
1998van Laar JAM, Rustum YM, Ackland SP, van Groeningen CJ, Peters GJ, 'Comparison of 5-fluoro-2 '-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer', EUROPEAN JOURNAL OF CANCER, 34 296-306 (1998)
1998Gurney HP, Ackland S, Gebski V, Farrell G, 'Factors affecting epirubicin pharmacokinetics and toxicity: Evidence against using body-surface area for dose calculation', JOURNAL OF CLINICAL ONCOLOGY, 16 2299-2304 (1998)
1998Ackland SP, 'Drug treatment of breast cancer', Australian Prescriber, 21 15-19 (1998)
1998Clarke S, Millward M, Findlay M, Ackland S, Hosie D, Abratt R, Goedhals L, 'Activity of the multi-targeted antifolate MTA (LY231514) in advanced non-small cell lung cancer (NSCLC)', ANNALS OF ONCOLOGY, 9 86-87 (1998)
1997Bishop JF, Dewar J, Toner GC, Tattersall MH, Olver IN, Ackland S, et al., 'Paclitaxel as first-line treatment for metastatic breast cancer', ONCOLOGY, 11 19-23 (1997)
1997Ackland SP, Garg MB, Dunstan RH, 'Simultaneous determination of dihydrofluorouracil and 5-fluorouracil in plasma by high-performance liquid chromatography', ANALYTICAL BIOCHEMISTRY, 246 79-85 (1997)
1997Bishop JF, Dewar J, Toner G, Tattersall MH, Olver I, Ackland S, et al., 'A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: Preliminary results', SEMINARS IN ONCOLOGY, 24 5-9 (1997)
1997Leong DCS, Kinlay S, Ackland S, Bonaventura A, Stewart JF, 'Low-risk febrile neutropenia in a medical oncology unit', AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 27 403-407 (1997)
1997Liu JP, Yajima Y, Li H, Ackland S, Akita Y, Stewart J, Kawashima S, 'Molecular interactions between dynamin and G-protein beta gamma-subunits in neuroendocrine cells', MOLECULAR AND CELLULAR ENDOCRINOLOGY, 132 61-71 (1997)
1996Peters GJ, Ackland SP, 'New antimetabolites in preclinical and clinical development', Expert Opinion on Investigational Drugs, 5 637-679 (1996)
1995BURMEISTER BH, DENHAM JW, OBRIEN M, JAMIESON GG, GILL PG, DEVITT P, et al., 'COMBINED-MODALITY THERAPY FOR ESOPHAGEAL-CARCINOMA - PRELIMINARY-RESULTS FROM A LARGE AUSTRALASIAN MULTICENTER STUDY', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 32 997-1006 (1995)
1995DENHAM JW, HAMILTON CS, CHRISTIE D, OBRIEN M, BONAVENTURA A, STEWART JF, et al., 'SIMULTANEOUS ADJUVANT RADIATION-THERAPY AND CHEMOTHERAPY IN HIGH-RISK BREAST-CANCER - TOXICITY AND DOSE MODIFICATION - A TRANS-TASMAN RADIATION ONCOLOGY GROUP MULTI-INSTITUTION STUDY', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 31 305-313 (1995)
1993Cooper SG, Bonaventura A, Ackland SP, Joseph DJ, Stewart JF, Hamilton CS, Denham JW, 'Pelvic radiotherapy with concurrent 5-fluorouracil modulated by leucovorin for rectal cancer: A phase II study', Clinical Oncology, 5 169-173 (1993)
1993Ackland SP, Hamilton CS, Joseph DJ, Denham JW, 'Phase I/II study of concurrent weekly carboplatin and radiation therapy in advanced head and neck cancer', Clinical Oncology, 5 133-138 (1993)
1990JOSEPH DJ, HAMILTON CS, DENHAM JW, ACKLAND SP, STEWART JF, 'WHITHER SCREENING MAMMOGRAPHY IN AUSTRALIA - ESTABLISHING A SATISFACTORY BASIS FOR FUNDING', MEDICAL JOURNAL OF AUSTRALIA, 152 545-546 (1990)
1989COOPER SG, DENHAM JW, HAMILTON CS, JOSEPH DJ, STEWART JF, ACKLAND SP, 'THE PRICE OF A FALSE-NEGATIVE RESULT OF MAMMOGRAPHY AND AN OVERENTHUSIASTIC LAY PRESS', MEDICAL JOURNAL OF AUSTRALIA, 150 664-664 (1989)
Show 92 more

Conference (24 outputs)

YearCitationAltmetricsLink
2013Girgis A, Bonaventura T, Bonevski B, Hogan M, Boyes A, Proietto T, et al., 'FEASIBILITY STUDY OF AN ONCOLOGY NURSE PRACTITIONER MODEL OF CARE IN A RURAL CANCER SETTING', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2013) [E3]
2012Upanal NN, Ackland S, Bonaventura A, McElduff P, 'Improved clinical outcomes in metastatic colorectal cancer patients on first-line chemotherapy with bevacizumab can be predicted by early rise in blood pressure', Asia-Pacific Journal of Clinical Oncology, Brisbane, Queensland (2012) [E3]
2012Goddard EM, Dhillon HM, Turner J, Kabourakis M, Beale PJ, Goodwin A, et al., 'The impact of physical activity on disease-free survival in patients with high-risk stage II or III colon cancer: One month screening results', Asia-Pacific Journal of Clinical Oncology, Brisbane (2012) [E3]
2012Upanal NN, Ackland SP, Bonaventura A, McElduff P, 'Early rise in blood pressure to predict clinical outcomes in metastatic colorectal cancer (mCRC) patients treated with first-line bevacizumab', JOURNAL OF CLINICAL ONCOLOGY, Chicago, IL (2012) [E3]
2012Sakoff JA, Garg MB, Lincz L, Adler K, Scorgie FE, Ackland S, 'Predicting chemotherapy-induced toxicity in cancer patients from peripheral blood telomere length', European Journal of Cancer, Barcelona, Spain (2012) [E3]
2010Sakoff JA, Garg M, Adler K, Scorgie FE, Lincz L, Ackland S, 'Short telomeres in PBMNC predicts for haematological toxicity in colorectal cancer patients treated with 5FU', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book, Sydney, NSW (2010) [E3]
2010Ackland S, 'Challenges in clinical trials design and management in the 21st century', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book, Sydney, NSW (2010) [E3]
2010Sakoff JA, Garg M, Adler K, Scorgie FE, Lincz L, Ackland S, 'Telomere length in peripheral blood mononuclear cells (PBMNC) predicts for leukopenia, neutropenia and mucositis in colorectal cancer patients treated with 5FU', AACR 101st Annual Meeting 2010. Abstracts, Washington, DC (2010) [E3]
2010Garg M, Sakoff JA, Ackland S, 'A simple HPLC method to measure plasma mitotane and its two main metabolites in adrenocortical cancer patients', AACR 101st Annual Meeting 2010. Abstracts, Washington, DC (2010) [E3]

Co-authors: Jennette Sakoff

2009Goldstein D, van Hazel G, Selva-Nayagam S, Ackland S, Shapiro J, Carroll S, et al., 'GOFURTGO trial (GFG): An AGITG multicenter phase II study of fixed dose rate gemcitabine-oxaliplatin (Gem-Ox) integrated with concomitant 5FU and 3-D conformal radiotherapy (5FU-3DRT) for the treatment of locally advanced pancreatic cancer (LAPC)', JOURNAL OF CLINICAL ONCOLOGY, Orlando, FL (2009) [E3]
2007Ackland S, Dhillon H, Jakob L, 'The COSA and Cooperative Groups Enabling Project: What is intended to be accomplished', Asia Pacific Journal of Clinical Oncology, Adelaide, SA (2007) [E3]
2007Ngan S, Fisher R, Mackay J, Solomon M, Burmeister B, Goldstein D, et al., 'Acute adverse events in a randomised trial of short course versus long course preoperative radiotherapy for T3 adenocarcinoma of rectum: a Trans-Tasman Radiation Oncology Group trial (TROG 01.04)', European Journal of Cancer Supplements, Barcelona, Spain (2007) [E3]
2007Sobrero A, Young S, Balcewicz M, Chiara S, Perez-Carrion R, Mainwaring P, et al., 'A large phase IV study of first-line bevacizumab plus irinotecan and infusional 5-FU/LV in metastatic CRC: AVIRI', Annals of Oncology, Barcelona, Spain (2007) [E3]
2007Sobrero A, Ackland S, Clarke S, Perez-Carrion R, Chiara S, Gapski J, et al., 'Final data from a large phase II trial of first-line bevacizurnab plus classic or modified FOLFIRI in metastatic colorectal cancer (CRC)', European Journal of Cancer Supplements, Barcelona, Spain (2007) [E3]
2007Ackland S, Dhillon H, 'Improving processes across all Cancer Cooperative Trials Groups through Standard Operating Procedures (SOPS)', Asia Pacific Journal of Clinical Oncology, Adelaide, SA (2007) [E3]
2006Girgis A, Boyes AW, Clinton-Mcharg T, Ackland S, Pr H, 'Proactive, routine monitoring and intervention to reduce the psychosocial impact of cancer and its treatment in outpatient oncology services', Psycho-Oncology:Journal of the psychological, social and behavioral dimension of cancer, Ferrara-Venice, Italy (2006) [E3]

Co-authors: Allison Boyes

2006Stockler MR, Sourjina T, Harvey V, Frances P, Byrne M, van Hazel G, et al., 'A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment.', BREAST CANCER RESEARCH AND TREATMENT, San Antonio, TX (2006)
2006Sobrero A, Ackland S, Carrion RP, Chiarra S, Clarke S, Giron CG, et al., 'Aviri, a large phase II trial of first-line bevacizumab plus infusional 5-FU/leucovorin and irinotecan (FOLFIRI) in metastatic CRC', ANNALS OF ONCOLOGY, Istanbul, TURKEY (2006)
2006Sobrero A, Ackland S, Perez Carrion R, Chiara S, Clarke S, Garcia Giron C, et al., 'First-line bevacizumab plus infusional 5-FU/irinotecan in metastatic CRC: Initial data from the AVIRI trial', ANNALS OF ONCOLOGY, Barcelona, SPAIN (2006)
2006Sobrero A, Ackland S, Carrion RP, Chiara S, Clarke S, Giron CG, et al., 'Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer.', JOURNAL OF CLINICAL ONCOLOGY, Atlanta, GA (2006)
2004Kacen L, Madjar I, Denham J, Ackland S, Aried S, 'The patient-other dynamics of the decision to forgo or stop active treatment for cancer', Palliative Medicine, Stresa, Italy (2004) [E3]
2003Smithers BM, Burmeister BH, Fitzgerald L, Gebski V, Denham J, Devitt P, et al., 'A randomized controlled trial of surgery alone compared with chemoradiation & surgery: a focus on the surgical outcomes', ANNALS OF SURGICAL ONCOLOGY, LOS ANGELES, CALIFORNIA (2003)
2002Sakoff JA, Ackland SP, Garg MB, Walkom CC, McCluskey A, 'Protein phosphatase 2A, a novel and unexplored anticancer target', EUROPEAN JOURNAL OF CANCER, FRANKFURT, GERMANY (2002)
2001Keath R, Stewart J, Ackland S, Bonaventura A, 'Guidelines for the use of colony stimulating factors in patients receiving adjuvant chemotherapy for breast cancer', Proceedings in European Journal of Cancer, Unknown (2001) [E3]
Show 21 more
Edit

Grants and Funding

Summary

Number of grants26
Total funding$11,750,376

- Indicates that the researcher may be seeking students for this project.

Click on a grant title below to expand the full details for that specific grant.

2014 (3 grants)

High Throughput Image Capture Platform for Translational Cancer Research$282,614
Funding Body: Cancer Institute NSW

Project Team
Conjoint Professor Stephen Ackland, Professor Rodney Scott, Professor John Forbes, Professor Xu Dong Zhang, Professor Marjorie Walker, Professor Hubert Hondermarck, Doctor Craig Gedye, Doctor Rick Thorne, Mr Loui Rassam, Doctor Stephen Braye
SchemeRole
Equipment GrantChief Investigator
Total AmountFunding StartFunding Finish
$282,61420142014
GNo:G1400626

Biobanking Stakeholder Network Pre-Operative Consent Project$55,580
Funding Body: Cancer Institute NSW

Project Team
Professor Rodney Scott, Conjoint Professor Stephen Ackland
SchemeRole
Community of Practice ProgramInvestigator
Total AmountFunding StartFunding Finish
$55,58020142014
GNo:G1301060

ProBBANG: Prospective study of Bevacizumab-induced Blood pressure and ANGiogenic factors as predictive biomarkers in colorectal cancer$20,868
Funding Body: Hunter Medical Research Institute

Project Team
Conjoint Professor Stephen Ackland
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$20,86820142014
GNo:G1301365

2013 (2 grants)

HMRI MRSP Infrastructure (12-16) – CANCER $991,860
Funding Body: Hunter Medical Research Institute

Project Team
Conjoint Professor Stephen Ackland
SchemeRole
NSW MRSP Infrastructure GrantChief Investigator
Total AmountFunding StartFunding Finish
$991,86020132016
GNo:G1300588

Investigation into a collaborative imaging database for NSW biobanks.$100,000
Funding Body: Cancer Institute NSW

Project Team
Professor Rodney Scott, Conjoint Professor Stephen Ackland, Assoc. Prof Nicholas Hawkins, Associate Professor Deborah Marsh
SchemeRole
Community of Practice ProgramInvestigator
Total AmountFunding StartFunding Finish
$100,00020132014
GNo:G1300902

2012 (3 grants)

The Hunter Cancer Biobank (HCB): Maximising community value through validation, annotation and distribution throughout NSW$292,300
Funding Body: Cancer Institute NSW

Project Team
Professor John Forbes, Conjoint Professor Stephen Ackland, Professor Rodney Scott, Conjoint Associate Professor Barbara Young, Professor Hubert Hondermarck, Emeritus Professor Leonie Ashman, Professor Xu Dong Zhang, Doctor Kelly Kiejda, Doctor Nikki Verrills, Doctor Jennette Sakoff, Ms Janine Lombard, Doctor Jude Weidenhofer, Doctor Pradeep Tanwar
SchemeRole
Infrastructure GrantsInvestigator
Total AmountFunding StartFunding Finish
$292,30020122014
GNo:G1200798

High-Resolution Isoelectric Phosphoprotein Signalling System for Signalling Research, Biomarker Validation and Drug Development – Equipment Grant$143,394
Funding Body: Hunter Medical Research Institute

Project Team
Doctor Rick Thorne, Professor Xu Dong Zhang, Professor Hubert Hondermarck, Conjoint Professor Stephen Ackland, Doctor Lisa Lincz, Doctor Jennette Sakoff, Emeritus Professor Leonie Ashman
SchemeRole
Project GrantInvestigator
Total AmountFunding StartFunding Finish
$143,39420122012
GNo:G1200555

Mitotane pharmacodynamics in Adrenocortical Cancer in children and adults $20,000
Funding Body: Hunter Medical Research Institute

Project Team
Conjoint Professor Stephen Ackland, Doctor Jennette Sakoff, Ms MADHU Garg
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$20,00020122013
GNo:G1200319

2011 (2 grants)

Hunter Translational Cancer Research Unit$1,693,333
Funding Body: Cancer Institute NSW

Project Team
Conjoint Professor Stephen Ackland, Emeritus Professor Leonie Ashman, Professor John Forbes, Laureate Professor Robert Sanson-Fisher, Conjoint Associate Professor Anthony Proietto, Professor Rodney Scott
SchemeRole
Translational Cancer Research UnitChief Investigator
Total AmountFunding StartFunding Finish
$1,693,33320112014
GNo:G1100545

HMRI MRSP Infrastructure (11-12)-Cancer $495,930
Funding Body: Hunter Medical Research Institute

Project Team
Conjoint Professor Stephen Ackland
SchemeRole
NSW MRSP Infrastructure GrantChief Investigator
Total AmountFunding StartFunding Finish
$495,93020112012
GNo:G1101207

2010 (2 grants)

Feasibility study of an oncology nurse practitioner model of care at improving outcomes in a rural cancer setting$557,634
Funding Body: Cancer Institute NSW

Project Team
Conjoint Professor Afaf Girgis, Conjoint Associate Professor Anthony Proietto, Associate Professor Billie Bonevski, Doctor Allison Boyes, Conjoint Professor Stephen Ackland, Doctor Anthony Bonaventura, Mr Douglas Bellamy
SchemeRole
Translational Health Service Research GrantInvestigator
Total AmountFunding StartFunding Finish
$557,63420102012
GNo:G0190563

HMRI MRSP Infrastructure Grant (10-11) - CANCER$504,071
Funding Body: Hunter Medical Research Institute

Project Team
Emeritus Professor Leonie Ashman, Conjoint Professor Stephen Ackland
SchemeRole
NSW MRSP Infrastructure GrantInvestigator
Total AmountFunding StartFunding Finish
$504,07120102010
GNo:G1100269

2009 (2 grants)

Provision of non-physical infrastructure support to enhance the breast cancer clinical trials research activities of the ANZ BCTG and its ability to build productive research collaborations$330,000
Funding Body: Cancer Institute NSW

Project Team
Professor John Forbes, Associate Professor Frances Boyle, Conjoint Professor Stephen Ackland, Professor Alan Coates
SchemeRole
Infrastructure GrantsInvestigator
Total AmountFunding StartFunding Finish
$330,00020092012
GNo:G0190219

MRSP Infrastructure (09-10) Cancer$283,916
Funding Body: Hunter Medical Research Institute

Project Team
Emeritus Professor Leonie Ashman, Conjoint Professor Stephen Ackland
SchemeRole
NSW MRSP Infrastructure GrantInvestigator
Total AmountFunding StartFunding Finish
$283,91620092010
GNo:G0900172

2008 (2 grants)

HMRI Cancer Research Program - MRSP Infrastructure$1,031,290
Funding Body: Hunter Medical Research Institute

Project Team
Conjoint Professor Stephen Ackland, Emeritus Professor Leonie Ashman, Professor John Forbes, Conjoint Professor Jim Denham, Conjoint Professor Peter Hersey, Professor Gordon Burns, Professor Adam McCluskey, Doctor Nikki Verrills
SchemeRole
NSW MRSP Infrastructure GrantChief Investigator
Total AmountFunding StartFunding Finish
$1,031,29020082009
GNo:G0188622

HMRI Senior Research Fellow$160,000
Funding Body: Hunter Medical Research Institute

Project Team
Professor John Attia, Emeritus Professor Maree Gleeson, Professor Rodney Scott, Conjoint Professor Vaughan Carr, Conjoint Professor Stephen Ackland, Professor Michael Hazelton, Professor Trevor Day
SchemeRole
Senior FellowshipInvestigator
Total AmountFunding StartFunding Finish
$160,00020082009
GNo:G0188558

2007 (1 grants)

(102) Hunter Medical Research Institute - Cancer$12,214
Funding Body: University of Newcastle

Project Team
Conjoint Professor Stephen Ackland
SchemeRole
Publication Performance GrantChief Investigator
Total AmountFunding StartFunding Finish
$12,21420072008
GNo:G0187977

2006 (1 grants)

PRC - Priority Research Centre for Bioinformatics, Biomarker Discovery & Information-Based Medicine (CIBM)$621,143
Funding Body: University of Newcastle

Project Team
Professor Pablo Moscato, Professor Rodney Scott, Emeritus Professor John Rostas, Professor John Forbes, Conjoint Professor Peter Hersey, Conjoint Professor Stephen Ackland, Conjoint Professor Wayne Smith, Emeritus Professor Peter Dunkley, Emeritus Professor Leonie Ashman, Professor John Attia, Associate Professor Phillip Dickson, Associate Professor Liz Milward, Professor Alistair Sim, Associate Professor Paul Tooney, Associate Professor Regina Berretta, Conjoint Professor David Sibbritt, Conjoint Professor Chris Levi, Professor Xu Dong Zhang, Conjoint Associate Professor Patricia Crock, Conjoint Associate Professor Jeannette Lechner-Scott
SchemeRole
Priority Research CentreInvestigator
Total AmountFunding StartFunding Finish
$621,14320062013
GNo:G0186919

2005 (3 grants)

Protocol development, web-based data collection and date quality assurance for all Cancer Cooperative Trials Groups$1,840,000
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Conjoint Professor Stephen Ackland, Professor Alan Coates, Professor John Zalcberg, Professor Max Wolf, Dr Kwun Fong, Professor John Forbes, Dr Helen Irving, Dr Guy Toner, Professor Michael Friedlander, Professor John Thompson, Dr David Ball, Professor John Simes
SchemeRole
Enabling Grants - Clinical Trials ResourcesChief Investigator
Total AmountFunding StartFunding Finish
$1,840,00020052010
GNo:G0184628

Enhancement of the ANZBCTG research program through the provision of infrastructure funding for essential management and operational personnel and other key activities $1,720,564
Funding Body: Cancer Institute NSW

Project Team
Professor John Forbes, Professor Alan Coates, Professor John Simes, Conjoint Professor Stephen Ackland
SchemeRole
Infrastructure GrantsInvestigator
Total AmountFunding StartFunding Finish
$1,720,56420052009
GNo:G0185068

Proactive monitoring and intervention to reduce the pyschosocial impact of cancer therapy$117,000
Funding Body: Cancer Institute NSW

Project Team
Conjoint Professor Afaf Girgis, Doctor Allison Boyes, Conjoint Professor Stephen Ackland
SchemeRole
Infrastructure GrantsInvestigator
Total AmountFunding StartFunding Finish
$117,00020052005
GNo:G0185057

2002 (1 grants)

New targets for chemotherapy: anti-cancer drugs that target protein phosphatases$10,000
Funding Body: University of Newcastle

Project Team
Professor Adam McCluskey, Conjoint Professor Stephen Ackland, Doctor Jennette Sakoff
SchemeRole
Project GrantInvestigator
Total AmountFunding StartFunding Finish
$10,00020022002
GNo:G0181459

2001 (2 grants)

Investigations into the biological functioning and prognostic value of novel metastatic marker for breast cancer.$420,665
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor Gordon Burns, Conjoint Professor Anthony Leong, Conjoint Professor Stephen Ackland
SchemeRole
Project GrantInvestigator
Total AmountFunding StartFunding Finish
$420,66520012003
GNo:G0179658

Using Genetics and Pharmacokinetics to Predict Toxicity of Chemotherapy.$11,000
Funding Body: University of Newcastle

Project Team
Conjoint Professor Stephen Ackland
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$11,00020012001
GNo:G0180063

2000 (1 grants)

Pre-treatment Uracil: Dihydrouacil Ratio as a Predictor of 5FU Pharmacokinetics and Myelotoxicity of Chemotherapy.$10,000
Funding Body: ARC (Australian Research Council)

Project Team
Conjoint Professor Stephen Ackland
SchemeRole
Small GrantChief Investigator
Total AmountFunding StartFunding Finish
$10,00020002000
GNo:G0178977

1999 (1 grants)

Selective Inhibitors of Protein Phosphatases as Anti-cancer agents$25,000
Funding Body: Hunter Medical Research Institute

Project Team
Doctor Jennette Sakoff, Professor Adam McCluskey, Conjoint Professor Stephen Ackland
SchemeRole
Research GrantInvestigator
Total AmountFunding StartFunding Finish
$25,00019991999
GNo:G0178390
Edit

Research Supervision

Number of current supervisions0

For supervisions undertaken at an institution other that the University of Newcastle, the institution name is listed below the program name.

Past Supervision

YearProgramSupervisor TypeResearch Title
2007PhD (Medicine)Co-SupervisorThe Patterns of Care for Patients with Lung Cancer in the Hunter Region, Australia (1996-2002)
2001Honours Biol Sc Not Elsewhere Classifd
University of Newcastle
Co-SupervisorPredicting myelotoxicity of 5-FU chemotherapy.
2001Honours Biol Sc Not Elsewhere Classifd
University of Newcastle
Co-SupervisorInfluence of telomere length and telomerase activity in bone marrow progenitor cells on the time required to fully regenerate the bone marrow after an autologous peripheral blood stem cell transplantation.
Edit

Conjoint Professor Stephen Ackland

Work Phone(02) 4921 1146
Cell / Mobile Phone0408 492868
Fax(02) 4968 0384
Email
PositionConjoint Professor
Medical Oncology
Faculty of Health and Medicine
The University of Newcastle, Australia
Focus AreaPharmacy and Experimental Pharmacology
Office
NM2,
Mater Hospital Level 3 - New Med 2,
Other
URL:www.newcastle.edu.au/profile/stephen-ackland